@article{oai:kanazawa-u.repo.nii.ac.jp:00047522,
 author = {武内, 章彦 and 棟居, 聖一 and 山本, 憲男 and 林, 克洋 and 三輪, 真嗣 and 谷口, 裕太 and 原島, 愛 and 山本, 靖彦 and 土屋, 弘行 and Higuchi, Takashi and Takeuchi, Akihiko and Munesue, Seiichi and Yamamoto, Norio and Hayashi, Katsuhiro and Kimura, Hiroaki and Miwa, Shinji and Inaki, Hiroyuki and Shimozaki, Shingo and Kato, Takashi and Aoki, Yu and Abe, Kensaku and Taniguchi, Yuta and Aiba, Hisaki and Murakami, Hideki and Harashima, Ai and Yamamoto, Yasuhiko and Tsuchiya, Hiroyuki},
 issue = {5},
 journal = {Cancer Medicine},
 month = {May},
 note = {Surgical resection is the only treatment for chondrosarcomas, because of their resistance to chemotherapy and radiotherapy; therefore, additional strategies are crucial to treat chondrosarcomas. Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor, which has been reported as a possible therapeutic target in certain malignancies including chondrosarcomas. In this study, we demonstrated that a nonsteroidal anti-inflammatory drug, zaltoprofen, could induce PPARγ activation and elicit anti-tumor effects in chondrosarcoma cells. Zaltoprofen was found to induce expressions of PPARγ mRNA and protein in human chondrosarcoma SW1353 and OUMS27 cells, and induce PPARγ-responsible promoter reporter activities. Inhibitory effects of zaltoprofen were observed on cell viability, proliferation, migration, and invasion, and the activity of matrix metalloproteinase-2 (MMP2); these effects were dependent on PPARγ activation and evidenced by silencing PPARγ. Moreover, we showed a case of a patient with cervical chondrosarcoma (grade 2), who was treated with zaltoprofen and has been free from disease progression for more than 2 years. Histopathological findings revealed enhanced expression of PPARγ and reduced expression of MMP2 after administration of zaltoprofen. These findings demonstrate that zaltoprofen could be a promising drug against the malignant phenotypes in chondrosarcomas via activation of PPARγ and inhibition of MMP2 activity. © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd., 29573200, 金沢大学医薬保健研究域医学系},
 pages = {1944--1954},
 title = {Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.},
 volume = {7},
 year = {2018}
}